Successful immunomodulating in AIDS patients with ursodeoxycholic acid—a pilot study

Abstract

SUMMARYBased on the positive therapeutic results with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis, in whom we observed a clinical improvement in conjunction with the normalization of the low pretreatment dipeptidyl peptidase (DPIV, CD26) expression of peripheral blood lymphocytes (PBL), we hypothesized that the very low DPIV expression in AIDS patients could be positively in¯uenced by UDCA. Four young male AIDS patients were therefore treated with 750 mg of UDCA for 4 months. The low CD26 expression (2±8% of the PBL versus 18±28% in healthy controls) at the beginning of the study rose to 10±16% after UDCA therapy. Simultaneously we observed a two-tothree-fold elevation of the absolute number of lymphocytes as well as a slight increase of CD4 cells. These effects were similar in all examined patients. Further investigations should be conducted on this potentially bene®cial effect of UDCA.

Systemic DPP4 activity is reduced during primary HIV‐1 infection and is associated with intestinal RORC+CD4+ cell levels: a surrogate marker candidate of HIV‐induced intestinal damage

“…sDPP4 was quantified before infection (N = 87), in primary HIV infection (PHI, N = 36), at three months post‐seroconversion (M3, N = 126) and six months post‐seroconversion (M6, N = 104). In most studies, the levels of sDDP4 are measured at the level of its enzymatic activity and absolute concentrations are more rarely presented . We measured both and as in previous studies , found a strong correlation between the concentration and enzymatic activity of sDDP4 ( R = 0.72, p < 0.0001 and Figure A).…”

“…DPP4 has been less studied in viral infections, with the exception of HCV . A study on HIV infection provided evidence that immunomodulation by Ursodeoxycholic acid can increase the number of CD4 + DPP4 + T cells in AIDS patients . Herein, we have studied for the first time sDPP4 levels in primary HIV infection, demonstrating that sDPP4 is severely decreased during PHI in two independent cohorts.…”

Plasma Metabolic Profiling Analysis of Gout Party on Acute Gout Arthritis Rats Based on UHPLC–Q–TOF/MS Combined with Multivariate Statistical Analysis

“…PCS is a microbial metabolite that is closely related to uremia and is the most common substance during uremia [47]. At excessive levels, PCS can increase renal fibrosis, decrease uric acid excretion by the kidneys, and stimulate uric acid accumulation, which can induce gout [48]. m–Methyl hippuric acid, also known as 3–methyl propionate, is an organic N–acyl–alpha amino acid synthesized from hippuric acid.…”

Steatohepatitis in HIV-Infected Subjects: Pathogenesis, Clinical Impact and Implications in Clinical Management

“…UDCA may have both cytoprotective and immunological effects, also in HIV-infected subjects [74]. To date, the role of UDCA treatment for NASH has been evaluated only in HIV-negative population.…”